Restart Life Sciences Announces Private Placement Financing

Executive Summary

• Restart Life Sciences Corp. announced a non‑brokered private placement of up to 10,000,000 units at CAD $0.10 per unit, targeting gross proceeds of up to CAD $1,000,000.
• Each unit consists of one common share and one transferable warrant allowing the purchase of an additional common share at CAD $0.10 for one year.
• Proceeds are earmarked for health‑food trials, potential acquisitions, and general working capital; units will be subject to a four‑month‑plus‑one‑day hold period.

Key Details

• Offering Size: Up to 10,000,000 Units (CAD $0.10 per Unit) → Maximum gross proceeds of CAD $1,000,000.
• Unit Composition: 1 common share + 1 transferable common share purchase warrant.
• Warrant Terms: Right to purchase one additional common share at CAD $0.10 per share; exercisable for a period of one (1) year from issuance.
• Use of Proceeds:
• Health‑food trial programs.
• Potential acquisitions related to brain health and wellness initiatives.
• General working capital.
• Hold Period: All securities issued are subject to a lock‑up of four months and one day from the date of issuance.
• Finder’s Fees: May be payable in accordance with CSE policies.
• Announcement Source: Newsfile Corp., released on behalf of Restart Life Sciences Corp.

Notable Quotes

(No direct quotes were provided in the release.)